279 ORAL Basal-like subtype of breast carcinoma predicts poor clinical outcome in patients with high-risk breast cancer treated with high-dose (HD) or dose-dense chemotherapy: Results of multivariate analysis from the WSG-AM-01 phase III trial

首页> 外文期刊>European Journal of Cancer Supplements >279 ORAL Basal-like subtype of breast carcinoma predicts poor clinical outcome in patients with high-risk breast cancer treated with high-dose (HD) or dose-dense chemotherapy: Results of multivariate analysis from the WSG-AM-01 phase III trial

【24h】

279 ORAL Basal-like subtype of breast carcinoma predicts poor clinical outcome in patients with high-risk breast cancer treated with high-dose (HD) or dose-dense chemotherapy: Results of multivariate analysis from the WSG-AM-01 phase III trial

机译：279 ORAL基底样乳腺癌亚型预示着大剂量（HD）或剂量密集化疗治疗的高危乳腺癌患者的临床结局较差：WSG-AM-01 III期试验的多因素分析结果

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2005年第2期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. [J] . Nitz UA, Mohrmann S, Fischer J, The Lancet . 2005,第9501期

机译：快速循环串联大剂量化疗加外周血干细胞支持与高剂量常规化疗在高危乳腺癌辅助治疗中的比较：一项多中心III期试验的结果。
2. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. [J] . Quintela Fandino M, Lopez JM, Hitt R, Journal of Clinical Oncology . 2006,第22期

机译：辅助化疗后外周血中存在乳腺癌特异性mRNA转录本，这预示着接受高剂量化疗和外周血干细胞支持治疗的高危乳腺癌患者的生存率较差。
3. Updated Survival Analysis after a Median Follow-up of 12 Years of an Anthracycline-Containing Adjuvant Prospective Multicentre, Randomised Phase III Trial on Dose-Dense Chemotherapy in Primary Node-Positive, High-Risk Breast Cancer Patients [J] . Reinisch M., Gluz O., Ataseven B., Breast care . 2019,第3期

机译：更新的存活分析后12年的含蒽丙氨酸辅助前景多期，随机期III试验在原发性阳性阳性，高危高危乳腺癌患者中进行随机态化化疗
4. Clinical Outcome of Breast and Ovarian Cancer Patients Treated after High-Dose Chemotherapy and Autologous Stem Cell Rescue with Theratope (STn-KLH) Cancer Vaccine: Theratope (STn-KLH) Cancer Vaccine following Autologous Transplant [C] . Leona A. Holmberg, Katherine A. Guthrie, Brenda M. Sandmaier Chemical glycobiology . -1

机译：大剂量化学疗法和自体干细胞拯救治疗的Theratope（STn-KLH）癌症疫苗治疗的乳腺癌和卵巢癌患者的临床结果：自体移植后的Theratope（STn-KLH）癌症疫苗
5. Analysis of quality of life data from a clinical trial in patients with advanced breast cancer with a comparison of different statistical approaches. [D] . Liu, Jianhua. 2002

机译：通过比较不同统计方法对晚期乳腺癌患者的临床试验的生活质量数据进行分析。
6. Updated Survival Analysis after a Median Follow-up of 12 Years of an Anthracycline-Containing Adjuvant Prospective Multicentre Randomised Phase III Trial on Dose-Dense Chemotherapy in Primary Node-Positive High-Risk Breast Cancer Patients [O] . Mattea Reinisch, Oleg Gluz, Beyhan Ataseven, 2019

机译：对原发于淋巴结阳性高风险的乳腺癌患者进行剂量密集型化疗的含蒽环类辅助佐治性前瞻性多中心随机III期试验的中位随访12年后的最新生存分析
7. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00 [O] . G. Fountzilas, U. Dafni, H. Gogas, 2008

机译：高风险乳腺癌患者的术后剂量 - 致密顺序化疗，高风险乳腺癌患者：Hellenic合作肿瘤学院的安全分析随机分配III审判他10/00

279 ORAL Basal-like subtype of breast carcinoma predicts poor clinical outcome in patients with high-risk breast cancer treated with high-dose (HD) or dose-dense chemotherapy: Results of multivariate analysis from the WSG-AM-01 phase III trial

著录项

相似文献

相关主题

期刊订阅